Skip to main content
logo
Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
395.25
-0.87 (-0.22%)
At close: Sep 8, 2025, 4:00 PM
395.77
+0.52 (0.13%)
After-hours: Sep 8, 2025, 7:19 PM EDT

Vertex Pharmaceuticals Revenue by Segment

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Trikafta and Kaftrio
10.39B10.29B10.19B9.81B9.50B9.29B8.94B8.63B---
Trikafta and Kaftrio Growth
9.44%10.80%13.95%13.59%13.46%15.77%16.36%17.33%---
Kalydeco
------475.50M499.20M525.80M539.20M553.20M569.30M592.30M636.90M
Kalydeco Growth
-------14.05%-12.31%-11.23%-15.34%-19.15%-21.52%-21.74%-17.99%
Orkambi
------326.00M392.60M475.80M501.10M510.70M547.30M585.60M685.00M
Orkambi Growth
-------36.17%-28.27%-18.75%-26.85%-33.81%-34.82%-33.54%-23.21%
Symdeko and Semkevi
------123.00M129.50M134.30M145.80M180.00M226.10M269.30M360.10M
Symdeko and Semkevi Growth
-------31.67%-42.72%-50.13%-59.51%-57.18%-51.64%-50.34%-37.97%

Revenue by Geography

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
United States
7.03B6.82B6.68B6.42B6.26B6.16B6.04B5.93B
United States Growth
12.27%10.75%10.67%8.37%7.47%7.35%5.98%5.21%
Europe
3.42B3.31B3.45B3.36B3.28B3.27B3.11B3.06B
Europe Growth
4.31%1.34%11.09%9.68%8.30%13.50%14.91%17.34%
Other
939.20M958.10M881.30M846.30M798.40M759.30M719.80M667.10M
Other Growth
17.64%26.18%22.44%26.86%22.36%28.11%36.87%45.31%

Operating Expense Breakdown

Period EndingJun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Research and Development
3.83B3.82B3.63B3.46B3.39B3.21B3.16B3.03B
Research and Development Growth
13.05%19.05%14.78%13.98%18.24%19.67%24.51%25.71%
Selling, General, and Administrative
1.57B1.52B1.46B1.46B1.35B1.24B1.14B1.03B
Selling, General, and Administrative Growth
16.52%22.60%28.83%40.67%32.41%27.57%20.31%3.96%
Acquired In-Process Research and Development
124.50M4.57B4.63B4.56B4.60B256.80M527.10M531.90M---------
Acquired In-Process Research and Development Growth
-97.29%1,680.14%778.09%757.06%802.47%-44.25%356.36%140.57%---------
Change in Value of Contingent Consideration
2.20M1.80M-500.00K-49.60M-48.70M-49.80M-51.60M500.00K--
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.